ATNM Kronos AI forecast
A 30-trading-day price forecast for Actinium Pharmaceuticals Inc. (Delaware) (ATNM) from Kronos AI, an open-source foundation model trained on candlestick charts.
Kronos AI's median forecast puts Actinium Pharmaceuticals Inc. (Delaware) at $1.06 on 2026-12-08, −25.4% from the last close of $1.42 on 2026-10-27. Eight out of ten sampled paths end between $1.04 and $1.10, and 0 of the 8 paths finish above today's price.
Forecast path
median, with the 10–90% band of the sampled pathsOpen the interactive forecast → Full analysis of ATNM
The forecast, week by week
| Date | Median | Low (10%) | High (90%) |
|---|---|---|---|
| 2026-11-03 | $1.38 | $1.34 | $1.44 |
| 2026-11-10 | $1.30 | $1.18 | $1.35 |
| 2026-11-17 | $1.09 | $1.05 | $1.12 |
| 2026-11-24 | $1.04 | $1.00 | $1.08 |
| 2026-12-01 | $1.06 | $1.00 | $1.08 |
| 2026-12-08 | $1.06 | $1.04 | $1.10 |
What is Kronos AI?
Kronos is an open-source foundation model for financial candlesticks, pre-trained on K-line data from more than 45 exchanges. Gnzub runs it on each stock's last 120 daily bars and samples several possible futures, so the forecast is a range of outcomes rather than one confident line. It is a statistical model, not an analyst: it reads price patterns only and knows nothing about news, earnings or the business.
Questions
- What is the Kronos AI forecast for ATNM?
- Kronos AI's median forecast for ATNM is $1.06 in 30 trading days, −25.4% from the last close, with a 10–90% range of $1.04 to $1.10.
- Is the ATNM Kronos forecast a buy or sell signal?
- No. It is the output of a statistical model that reads price history only. It is not investment advice, and the range shows how uncertain the model is.
- How often is the forecast updated?
- The forecasts are regenerated regularly; this one starts from the close of 2026-10-27.
Kronos forecasts for similar companies
- LLY — Eli Lilly and Company
- JNJ — Johnson & Johnson
- ABBV — AbbVie Inc.
- MRK — Merck & Company Inc.
- NVS — Novartis AG
- AZN — AstraZeneca PLC